Thijs Bosch, CEO of The Protein Brewery, discusses the company's recent achievement of receiving a positive EFSA opinion for their novel mycelium-based ingredient, Fermotein. This milestone, after nearly five years of regulatory process, means that the ingredient is considered safe for sale in the European market once formal EC authorization is granted. Bosch emphasizes the importance of internal regulatory expertise, budgeting for global regulatory approvals, and the potential blocking risk from member states in obtaining EU-wide authorization.

The EFSA approval has had a significant impact on investors and customers, increasing confidence in the product and execution of The Protein Brewery. With the approval, corporate customers now have a clearer timeline for formulating with the ingredient and getting products to market. This milestone signifies a shift from hypothetical discussions to concrete plans for commercialization, shaping the future direction of the company's conversations from "if" to "when and how."